Diana M. Escolar
Keine laufenden Positionen mehr
Karriereverlauf von Diana M. Escolar
Ehemalige bekannte Positionen von Diana M. Escolar
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
AVROBIO, INC. | Technik-/Wissenschafts-/F&E-Leiter | 19.01.2021 | 26.10.2021 |
VIRIDIAN THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2018 | 01.01.2021 |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2011 | 01.09.2017 |
The Johns Hopkins University | Corporate Officer/Principal | 01.01.2010 | 01.01.2017 |
CINRG | Direktor/Vorstandsmitglied | 01.01.2000 | 01.01.2007 |
Gründer | 01.01.2000 | 01.01.2007 | |
Children's National Hospital (District of Columbia)
Children's National Hospital (District of Columbia) Hospital/Nursing ManagementHealth Services Children's Hospital is a non-profit organization which engages in the provision of healthcare services. It offers pediatric and adolescent services, cardiac surgery, colorectal program, neurosurgery, oncology, and orthopedic surgery and sports medicine. The company was founded in 1870 and is headquartered in Washington, DC. | Corporate Officer/Principal | - | - |
George Washington University School of Medicine & Health | Corporate Officer/Principal | - | - |
Ausbildung von Diana M. Escolar
Universidad de Buenos Aires | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 8 |
Argentinien | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 4 |
Health Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AVROBIO, INC. | Health Technology |
VIRIDIAN THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Children's National Hospital (District of Columbia)
Children's National Hospital (District of Columbia) Hospital/Nursing ManagementHealth Services Children's Hospital is a non-profit organization which engages in the provision of healthcare services. It offers pediatric and adolescent services, cardiac surgery, colorectal program, neurosurgery, oncology, and orthopedic surgery and sports medicine. The company was founded in 1870 and is headquartered in Washington, DC. | Health Services |
CINRG | |
Akashi Therapeutics Inc
Akashi Therapeutics Inc Pharmaceuticals: MajorHealth Technology Akashi Therapeutics Inc is a clinical stage biopharmaceutical company based in Cambridge, MA with subsidiaries in the United States. The private company has been granted orphan designation for DMD in both the US and Europe. The American company's mission is to develop treatments for Duchenne muscular dystrophy and other rare pediatric diseases. Akashi is developing a cocktail of medications with the goal of transforming Duchenne from a 100% fatal, aggressive muscle-wasting disease to a chronic, manageable condition. The application of HT-100 to DMD and other fibrotic diseases is based on pioneering work by Dr. Mark Pines at the Volcani Institute. Dosing and new patient enrollment in the phase 1b/2a clinical program have been suspended. The company was founded by leading patient organizations and biotechnology industry veterans and is managed by a seasoned team of drug development experts. The company was founded by Marc B. Blaustein, Thomas C. Wicka. | Health Technology |
- Börse
- Insiders
- Diana M. Escolar
- Erfahrung